Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Adva Date : 12/16/2009 @ 8:30AM Source : PR Newswire Stock : (KERX) http://ih.advfn.com/p.php?pid=nmona&article=40785755&symbol=KERX